Research ExplorerPublicationsInhibin Alpha Expression in Human Tumors: A Tissue Microarra...

Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors

Standard

Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors. / Weidemann, Sören; Noori, Nessar Ahmad; Lennartz, Maximilian; Reiswich, Viktor; Dum, David; Menz, Anne; Chirico, Viktoria; Hube-Magg, Claudia; Fraune, Christoph; Bawahab, Ahmed Abdulwahab; Bernreuther, Christian; Simon, Ronald; Clauditz, Till S; Sauter, Guido; Hinsch, Andrea; Kind, Simon; Jacobsen, Frank; Steurer, Stefan; Minner, Sarah; Burandt, Eike; Marx, Andreas H; Krech, Till; Lebok, Patrick; Büscheck, Franziska; Höflmayer, Doris.

In: BIOMEDICINES, Vol. 10, No. 10, 2507, 07.10.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Weidemann, S, Noori, NA, Lennartz, M, Reiswich, V, Dum, D, Menz, A, Chirico, V, Hube-Magg, C, Fraune, C, Bawahab, AA, Bernreuther, C, Simon, R, Clauditz, TS, Sauter, G, Hinsch, A, Kind, S, Jacobsen, F, Steurer, S, Minner, S, Burandt, E, Marx, AH, Krech, T, Lebok, P, Büscheck, F & Höflmayer, D 2022, 'Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors', BIOMEDICINES, vol. 10, no. 10, 2507. https://doi.org/10.3390/biomedicines10102507

APA

Weidemann, S., Noori, N. A., Lennartz, M., Reiswich, V., Dum, D., Menz, A., Chirico, V., Hube-Magg, C., Fraune, C., Bawahab, A. A., Bernreuther, C., Simon, R., Clauditz, T. S., Sauter, G., Hinsch, A., Kind, S., Jacobsen, F., Steurer, S., Minner, S., ... Höflmayer, D. (2022). Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors. BIOMEDICINES, 10(10), [2507]. https://doi.org/10.3390/biomedicines10102507

Vancouver

Weidemann S, Noori NA, Lennartz M, Reiswich V, Dum D, Menz A et al. Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors. BIOMEDICINES. 2022 Oct 7;10(10). 2507. https://doi.org/10.3390/biomedicines10102507

Bibtex

@article{b6471e5bec604475a320524c6a0e17c5,
title = "Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors",
abstract = "As a result of its expression in corresponding normal cell types, inhibin alpha (INHA) is used as an immunohistochemical marker for adrenocortical neoplasms and testicular or ovarian sex cord stromal tumors. However, other tumors can also express INHA. To comprehensively determine INHA expression in cancer, a tissue microarray containing 15,012 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry. INHA positivity was found in 72 of 134 tumor categories, including 26 categories with ≥1 strongly positive case. A moderate to strong INHA positivity was found in 100% of 37 granulosa cell tumors of the ovary, 100% of 43 other sex cord stromal tumors of the ovary/testis, 100% of 31 granular cell tumors, 78.5% of 28 adenomas, 44% of 25 carcinomas of the adrenal cortex, and 46.7% of 15 pancreatic acinar cell carcinomas. At least a weak INHA positivity was seen in <33% of cases of 46 additional tumor entities. In summary, these data support the use of INHA antibodies for detecting sex cord stromal tumors, granular cell tumors, and adrenocortical neoplasms. Since INHA can also be found in other tumor entities, INHA immunohistochemistry should only be considered as a part of any panel for the distinction of tumor entities.",
author = "S{\"o}ren Weidemann and Noori, {Nessar Ahmad} and Maximilian Lennartz and Viktor Reiswich and David Dum and Anne Menz and Viktoria Chirico and Claudia Hube-Magg and Christoph Fraune and Bawahab, {Ahmed Abdulwahab} and Christian Bernreuther and Ronald Simon and Clauditz, {Till S} and Guido Sauter and Andrea Hinsch and Simon Kind and Frank Jacobsen and Stefan Steurer and Sarah Minner and Eike Burandt and Marx, {Andreas H} and Till Krech and Patrick Lebok and Franziska B{\"u}scheck and Doris H{\"o}flmayer",
year = "2022",
month = oct,
day = "7",
doi = "10.3390/biomedicines10102507",
language = "English",
volume = "10",
journal = "BIOMEDICINES",
issn = "2227-9059",
publisher = "MDPI AG",
number = "10",

}

RIS

TY - JOUR

T1 - Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors

AU - Weidemann, Sören

AU - Noori, Nessar Ahmad

AU - Lennartz, Maximilian

AU - Reiswich, Viktor

AU - Dum, David

AU - Menz, Anne

AU - Chirico, Viktoria

AU - Hube-Magg, Claudia

AU - Fraune, Christoph

AU - Bawahab, Ahmed Abdulwahab

AU - Bernreuther, Christian

AU - Simon, Ronald

AU - Clauditz, Till S

AU - Sauter, Guido

AU - Hinsch, Andrea

AU - Kind, Simon

AU - Jacobsen, Frank

AU - Steurer, Stefan

AU - Minner, Sarah

AU - Burandt, Eike

AU - Marx, Andreas H

AU - Krech, Till

AU - Lebok, Patrick

AU - Büscheck, Franziska

AU - Höflmayer, Doris

PY - 2022/10/7

Y1 - 2022/10/7

N2 - As a result of its expression in corresponding normal cell types, inhibin alpha (INHA) is used as an immunohistochemical marker for adrenocortical neoplasms and testicular or ovarian sex cord stromal tumors. However, other tumors can also express INHA. To comprehensively determine INHA expression in cancer, a tissue microarray containing 15,012 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry. INHA positivity was found in 72 of 134 tumor categories, including 26 categories with ≥1 strongly positive case. A moderate to strong INHA positivity was found in 100% of 37 granulosa cell tumors of the ovary, 100% of 43 other sex cord stromal tumors of the ovary/testis, 100% of 31 granular cell tumors, 78.5% of 28 adenomas, 44% of 25 carcinomas of the adrenal cortex, and 46.7% of 15 pancreatic acinar cell carcinomas. At least a weak INHA positivity was seen in <33% of cases of 46 additional tumor entities. In summary, these data support the use of INHA antibodies for detecting sex cord stromal tumors, granular cell tumors, and adrenocortical neoplasms. Since INHA can also be found in other tumor entities, INHA immunohistochemistry should only be considered as a part of any panel for the distinction of tumor entities.

AB - As a result of its expression in corresponding normal cell types, inhibin alpha (INHA) is used as an immunohistochemical marker for adrenocortical neoplasms and testicular or ovarian sex cord stromal tumors. However, other tumors can also express INHA. To comprehensively determine INHA expression in cancer, a tissue microarray containing 15,012 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry. INHA positivity was found in 72 of 134 tumor categories, including 26 categories with ≥1 strongly positive case. A moderate to strong INHA positivity was found in 100% of 37 granulosa cell tumors of the ovary, 100% of 43 other sex cord stromal tumors of the ovary/testis, 100% of 31 granular cell tumors, 78.5% of 28 adenomas, 44% of 25 carcinomas of the adrenal cortex, and 46.7% of 15 pancreatic acinar cell carcinomas. At least a weak INHA positivity was seen in <33% of cases of 46 additional tumor entities. In summary, these data support the use of INHA antibodies for detecting sex cord stromal tumors, granular cell tumors, and adrenocortical neoplasms. Since INHA can also be found in other tumor entities, INHA immunohistochemistry should only be considered as a part of any panel for the distinction of tumor entities.

U2 - 10.3390/biomedicines10102507

DO - 10.3390/biomedicines10102507

M3 - SCORING: Journal article

C2 - 36289769

VL - 10

JO - BIOMEDICINES

JF - BIOMEDICINES

SN - 2227-9059

IS - 10

M1 - 2507

ER -